January 31, 2017
Teva launches two asthma products in 2017 to compete with GSK
Teva’s two asthma treatments for patients older than 12 has been approved by the US Food and Drug Administration (FDA).
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Teva
January 31, 2017
US Court rules in Mylan’s favor, another decision against Teva
Israel’s largest drugmaker, Teva, has came up short yet again against a US courts regarding patent infringement cases.
January 31, 2017
US Court rules in Mylan’s favor, another decision against Teva
Israel’s largest drugmaker, Teva, has came up short yet again against a US courts regarding patent infringement cases.
January 30, 2017
Another USA laswusit against Teva, Aralez charges for 4 patent infringements
Aralez Pharmaceuticals will press charges against Teva in the USA for infringing four patents.
January 13, 2017
Eli Lilly v. Teva Parenteral Medicines over vitamin regimen patent for Alimta
U.S. Court of Appeals for the Federal Circuit has upheld the district court’s decision and ruled in the Eli Lilly’s favor regarding validity and infringement of the vitamin regimen patent for Alimta (pemetrexed for injection).
January 6, 2017
India’s Natco cleared to sell generic version of Teva’s leukemia treatment Trenda in USA
Indian drugmaker Natco Pharma has gotten the approval from the U.S. regulator for generic version of Teva’s leukemia treatment Trenda (Bendamustine Hydrochloride powder for Injection).
December 23, 2016
Israeli’s largest drugmaker Teva agrees to pay U.S. government $519M over foreign bribery charges
Israeil’s largest drugmaker Teva Pharmaceuticals Industries has settled with the United States government over international bribery of government officials in…
October 18, 2016
Teva buys Anda from Allergan
Teva Pharmaceutical Industries, an NYSE and TASE listed pharmaceutical company has completed its acquisition of Anda, Inc., a distributor of…
November 30, 2015
Teva and Takeda are forming a new joint venture to operate generics in Japan
Teva and Takeda are forming a new joint venture to operate in Japan
November 26, 2015
Teva to receive global development and commercial rights to Hemtares’ novel CGRP antagonists
Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Sosei Group’s subsidiary Heptares, for the treatment of migraine.